ES2167727T3 - Microparticulas de gel compuesto como vectores de principios activos. - Google Patents

Microparticulas de gel compuesto como vectores de principios activos.

Info

Publication number
ES2167727T3
ES2167727T3 ES97914410T ES97914410T ES2167727T3 ES 2167727 T3 ES2167727 T3 ES 2167727T3 ES 97914410 T ES97914410 T ES 97914410T ES 97914410 T ES97914410 T ES 97914410T ES 2167727 T3 ES2167727 T3 ES 2167727T3
Authority
ES
Spain
Prior art keywords
phytosanitary
nutritional
controllable
drugs
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97914410T
Other languages
English (en)
Inventor
Alain Lemercier
Remi Meyrueix
Sylvain Huille
Gerard Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Technologies SA
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Application granted granted Critical
Publication of ES2167727T3 publication Critical patent/ES2167727T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A VECTORES DE TRANSPORTE DE PRINCIPIOS ACTIVOS (PA) MEDICAMENTOSOS, NUTRICIONALES, FITOSANITARIOS O COSMETICOS. UNO DE LOS OBJETIVOS ESENCIALES DE LA INVENCION ES OBTENER PARTICULAS DE VECTORIZACION (PV) DE PA DE BAJA GRANULOMETRIA, CONTROLABLE Y AJUSTABLE, PROTECTORAS DEL PA, BIOCOMPATIBLES, BIODEGRADABLES, NO INMUNOGENAS, ESTABLES, EXENTAS DE DISOLVENTE, NO DESNATURALIZADORAS DEL PA Y QUE PERMITAN LA LIBERACION DE ESTE ULTIMO. LA INVENCION CUMPLE DICHO OBJETIVO CON UNAS MICROPARTICULAS DE ESTRUCTURA COHESIVA REALIZADAS EN UN GEL COMPOSITE, ESTABLE E INTEGRO DESDE EL PUNTO DE VISTA FISICO Y QUIMICO, Y QUE COMPRENDE ACEITE (I), POR EJEMPLO ACEITE DE COCO, UNA FASE ACUOSA (II) Y UN COPOLIAMINOACIDO LINEAL NO RETICULADO DE TIPO LEU/GLU (ESTADISTICO O DIBLOQUE). ESTAS PV TIENEN UN TAMAÑO CONTROLABLE Y AJUSTABLE ENTRE 0,05 Y 500 MI . APLICACION: VECTORIZACION DE MEDICAMENTOS, NUTRIENTES Y PRODUCTOS FITOSANITARIOS O COSMETICOS.
ES97914410T 1996-03-15 1997-03-14 Microparticulas de gel compuesto como vectores de principios activos. Expired - Lifetime ES2167727T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9603546A FR2746035B1 (fr) 1996-03-15 1996-03-15 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications

Publications (1)

Publication Number Publication Date
ES2167727T3 true ES2167727T3 (es) 2002-05-16

Family

ID=9490410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97914410T Expired - Lifetime ES2167727T3 (es) 1996-03-15 1997-03-14 Microparticulas de gel compuesto como vectores de principios activos.

Country Status (12)

Country Link
US (1) US6180141B1 (es)
EP (1) EP0888110B1 (es)
JP (1) JP2000507934A (es)
AT (1) ATE206912T1 (es)
AU (1) AU2166097A (es)
CA (1) CA2249274A1 (es)
DE (1) DE69707433T2 (es)
DK (1) DK0888110T3 (es)
ES (1) ES2167727T3 (es)
FR (1) FR2746035B1 (es)
PT (1) PT888110E (es)
WO (1) WO1997034584A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
FR2801226B1 (fr) * 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
FR2814952B1 (fr) * 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
FR2814951B1 (fr) * 2000-10-06 2003-01-17 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs hydrophiles (insuline) et leur mode de preparation
FR2822834B1 (fr) 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
US7122057B2 (en) * 2001-04-12 2006-10-17 Therics, Llc Method and apparatus for engineered regenerative biostructures such as hydroxyapatite substrates for bone healing applications
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
DE60323474D1 (de) 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
FR2860516B1 (fr) 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
FR2873040B1 (fr) * 2004-07-19 2007-11-30 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US20060224095A1 (en) * 2005-04-05 2006-10-05 University Of New Hampshire Biocompatible polymeric vesicles self assembled from triblock copolymers
JP5329949B2 (ja) * 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
FR2910318B1 (fr) * 2006-12-20 2009-07-03 Flamel Technologies Sa Dispersion de polyaminoacides dans une phase lipidique continue.
FR2914188B1 (fr) * 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
WO2010068432A1 (en) 2008-11-25 2010-06-17 Ecole Polytechnique Federale De Lausanne (Epfl) Block copolymers and uses thereof
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CN104961827A (zh) 2010-04-06 2015-10-07 阿格罗塞文公司 农用化学品的特异性输送
ES2634547T3 (es) 2010-08-26 2017-09-28 Agrosavfe N.V. Composiciones para el tratamiento de semillas
WO2012025602A1 (en) 2010-08-26 2012-03-01 Vib Vzw Insect binding antibodies
US10226417B2 (en) * 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CA2851040A1 (en) 2011-10-06 2013-04-11 Agrosavfe N.V. Manufacturing of specifically targeting microcapsules
ITMI20111866A1 (it) 2011-10-13 2013-04-14 Bio Ker S R L Polietilenglicoli modificati e loro complessi supramolecolari con macromolecole biologicamente attive
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
US9968092B2 (en) 2014-04-17 2018-05-15 Basf Se Combination of novel nitrification inhibitors and biopesticides as well as combination of (thio)phosphoric acid triamides and biopesticides
EP3177143A2 (en) 2014-04-17 2017-06-14 Basf Se Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides
EP3253209A1 (en) 2015-02-06 2017-12-13 Basf Se Pyrazole compounds as nitrification inhibitors
MX2017014459A (es) 2015-05-12 2018-03-16 Basf Se Compuestos de tioeter como inhibidores de la nitrificacion.
AU2017267129A1 (en) 2016-05-18 2018-11-22 Basf Se Capsules comprising benzylpropargylethers for use as nitrification inhibitors
IL275726B2 (en) 2018-01-09 2024-06-01 Basf Se Silylethynyl hetaryl compounds as nitrification inhibitors
PE20211754A1 (es) 2018-02-28 2021-09-06 Basf Se Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificacion
BR112020016425A2 (pt) 2018-02-28 2020-12-15 Basf Se Uso de composto de alcoxipirazol, composição para uso na redução da nitrificação, mistura agroquímica e métodos de redução da nitrificação e de tratamento de fertilizante ou composição
WO2019166558A1 (en) 2018-02-28 2019-09-06 Basf Se Use of pyrazole propargyl ethers as nitrification inhibitors
WO2019229624A1 (en) * 2018-05-27 2019-12-05 The State Of Israel, Ministry Of Agriculture & Rural Development Agricultural Research Organization Single cell encapsulation via pickering emulsion for bio-pesticides application
WO2020002472A1 (en) 2018-06-28 2020-01-02 Basf Se Use of alkynylthiophenes as nitrification inhibitors
DK3826983T3 (da) 2018-07-23 2024-08-05 Basf Se Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere
US12151991B2 (en) 2018-07-23 2024-11-26 Basf Se Use of a substituted thiazolidine compound as nitrification inhibitor
CN116829521A (zh) 2021-02-02 2023-09-29 巴斯夫欧洲公司 Dcd和烷氧基吡唑作为硝化抑制剂的协同增效作用
EP4341245A1 (en) 2021-05-21 2024-03-27 Basf Se Use of ethynylpyridine compounds as nitrification inhibitors
EP4341248A1 (en) 2021-05-21 2024-03-27 Basf Se Use of an n-functionalized alkoxy pyrazole compound as nitrification inhibitor
BR112023027004A2 (pt) 2021-06-21 2024-03-12 Basf Se Estrutura de metal-orgânica, uso da estrutura de metal-orgânica, composição para uso na redução da nitrificação, mistura agroquímica e métodos de redução da nitrificação, de tratamento de fertilizante ou composição de fertilizante e de preparação de uma estrutura de metal-orgânica
EP4451851A1 (en) 2021-12-23 2024-10-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. A novel glv-phenolamide: biosynthesis and function in protecting plants from herbivore attack
WO2023203066A1 (en) 2022-04-21 2023-10-26 Basf Se Synergistic action as nitrification inhibitors of dcd oligomers with alkoxypyrazole and its oligomers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4976968A (en) * 1989-02-24 1990-12-11 Clinical Technologies Associates, Inc. Anhydrous delivery systems for pharmacological agents
GB2260080A (en) * 1991-10-04 1993-04-07 Rhone Poulenc Rorer Ltd Gelled alginate compositions
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation

Also Published As

Publication number Publication date
WO1997034584A1 (fr) 1997-09-25
JP2000507934A (ja) 2000-06-27
FR2746035A1 (fr) 1997-09-19
EP0888110B1 (fr) 2001-10-17
DE69707433D1 (de) 2001-11-22
EP0888110A1 (fr) 1999-01-07
PT888110E (pt) 2002-04-29
DK0888110T3 (da) 2002-02-04
AU2166097A (en) 1997-10-10
US6180141B1 (en) 2001-01-30
DE69707433T2 (de) 2002-06-06
FR2746035B1 (fr) 1998-06-12
ATE206912T1 (de) 2001-11-15
CA2249274A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
ECSP10010352A (es) Gel de quitosano para aplicaciones dermatologicas, proceso de obtencion y uso del mismo
ES2094626T3 (es) Geles acuosos que contienen unas microesferas huecas expandidas.
ES2064908T3 (es) Empaquetamiento para microdosis de medicamento en polvo para inhalacion.
ES2147272T3 (es) Composicion inductora de apoptosis que comprende un factor que aumenta el porcentaje intracelular de metional o de la malondialdehido.
SV1995000010A (es) Prenda absorbente con un manejo mejorado de las emanaciones
ES2179829T3 (es) Preparacion de hidrogel de liberacion prolongada.
AR017197A1 (es) Formulacion de hidrogel farmaceutica, dispositivos de suministro de droga, metodo para eliminar sineresis, y metodos para preparar formulaciones farmaceuticas.
AR073519A1 (es) Portador de agentes activos liberados de forma controlada
ES2171467T3 (es) Venda reabsorbible para heridas vasculares.
ES2155931T3 (es) Forma de administracion de un agente activo de liberacion prolongada en banda.
AR008493A1 (es) Recipiente flexible de plastico para almacenamiento separado espacialmente y, optativamente, esterilizacion selectiva de ingrediente de preparaciones de uso parenteral o enteral, y uso del mismo
ES2134355T3 (es) Copolimeros elastomeros termoplasticos y composiciones para el cuidado del cabello y de la piel que los contienen.
FR2746035B1 (fr) Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
ES2100100T3 (es) Composicion para aplicacion topica que contiene una lipasa y un precursor de agente activo.
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
HN2003000206A (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
ES2127375T3 (es) Procedimiento de administracion de un farmaco oftalmico.
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
ES2173638T3 (es) Esferoides que contienen tiagabina, procedimiento de fabricacion y composiciones farmaceuticas.
CY1105849T1 (el) Χρηση αντισηπτικων στην εμπορικη κατασκευη φαρμακευτικου παρασκευασματος προς αποτροπη ή θepαπεια εναντι φλεγμονων εντος του ανθρωπινου σωματος
AR037885A1 (es) Un articulo absorbente con una composicion que tiene una distribucion pareja
CN107303288A (zh) 一种膜剂的生产方法及其产品
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
PT1121117E (pt) Acondicionamento de uma preparacao de oxaliplatina